Martin Shkreli, the controversial former hedge fund manager known as “Pharma Bro,” questioned but ultimately defended Palantir Technologies Inc.‘s (NYSE:PLTR) growth projections on Wednesday, calling analysis of the company’s $4 million average revenue per customer “flawed.”
What Happened: Shkreli noted that a common analysis of Palantir suggests only around 20,000 companies can afford its $4 million data analytics suite. He pointed out that some valuation models assume every one of these companies will adopt Palantir’s services by 2035, justifying its current valuation.
He noted that Palantir’s software might generate a positive return on investment regardless of budget constraints, its per-seat pricing model could expand market reach, and the company will likely diversify its product offerings.
However, he acknowledged competitive threats from Snowflake Inc. (NYSE:SNOW), Databricks, and AI startups, while questioning whether any enterprise software company has achieved $50 billion in high-margin license revenue.
interestingly, the analysis is flawed in a few ways.
1) software like this might SAVE you money, budget is irrelevant when ROIC is + 2) PLTR prices software per seat, so i expect their ARPC would decline over time, allowing them to reach more customers 3) they will put out more…
Why It Matters: Palantir’s stock has surged over 50% since President Donald Trump‘s November election victory, making it the S&P 500’s top performer during that period. The company recently joined the S&P 100 index, replacing Dow Inc., effective Mar 24.
The data analytics firm’s market performance has been driven by its artificial intelligence capabilities, with recent analyst price targets averaging $123.67 among Wedbush Securities, Loop Capital, and Citigroup—implying a 46% upside from current levels.
According to Benzinga Edge Ranking, Palantir outperforms Snowflake in momentum but lags in growth and value metrics.